Key statistics
As of last trade, Acrivon Therapeutics Inc (ACRV:NMQ) traded at 6.61, 107.11% above the 52 week low of 3.19 set on Feb 13, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 6.45 |
---|---|
High | 6.63 |
Low | 6.33 |
Bid | 6.62 |
Offer | 6.69 |
Previous close | 6.44 |
Average volume | 54.00k |
---|---|
Shares outstanding | 30.97m |
Free float | 18.74m |
P/E (TTM) | -- |
Market cap | 199.46m USD |
EPS (TTM) | -2.70 USD |
Data delayed at least 15 minutes, as of Nov 22 2024 19:26 GMT.
More ▼
- Acrivon Therapeutics Reports Third Quarter 2024 Financial Results and Business Highlights
- Acrivon Therapeutics to Present Data Demonstrating Deployment of its AP3 Platform for Streamlined Drug Discovery and Clinical Development at Two Scientific Conferences - Human Proteome Organization World Congress and EORTC-NCI-AACR Symposium
- Acrivon Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
- Acrivon Therapeutics Announces Initial Patient Dosing in Phase 1 Trial of ACR-2316, a Novel WEE1/PKMYT1 Inhibitor Designed Using AP3 for Superior Single-Agent Activity
- Acrivon Therapeutics Reports Positive Endometrial Cancer Data from Ongoing ACR-368 Registrational Intent Phase 2 Study at ESMO, Advancement of ACR-2316 into Clinic Ahead of Timelines, and Progress on its AP3 Interactome for Proprietary Data Analysis
- Acrivon Therapeutics to Present at the Cantor Global Healthcare Conference
- Acrivon Therapeutics to Host Virtual Investor Event to Review Positive Phase 2 Clinical Data of ACR-368 Presented at ESMO and Pipeline Progress, Including Clinical Candidate ACR-2316
- Acrivon Therapeutics Reports Second Quarter 2024 Financial Results and Business Highlights
- Acrivon Therapeutics to Present at the Jefferies Global Healthcare Conference
- Acrivon Therapeutics Reports First Quarter 2024 Financial Results and Business Highlights
More ▼